Compare Merck & Co., Inc. (MRK) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Vanguard Total World Stock Index Fund ETF — how do they compare? Merck & Co., Inc. trades at $148.1 (market cap $366.28B), while Vanguard Total World Stock Index Fund ETF trades at $160.36. The key difference: Merck & Co., Inc. pays a 2.29% dividend while Vanguard Total World Stock Index Fund ETF pays none. Which is the better fit depends on your goals.
| MRK | VT | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $156.43 | $162.39 |
52-Week Low | $77.60 | $134.19 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
VT trades at $160.92, down 0.5% on the day, with a bullish technical signal driven by moving averages and neutral oscillators. The ETF offers broad global equity diversification with over 10,000 stocks and a low 0.06% expense ratio. Recent institutional activity shows mixed positioning, with some firms increasing stakes while others reduced holdings.
The outlook remains favorable for long-term investors seeking global exposure, supported by cost efficiency and diversification benefits. Risks include trade policy uncertainty and market volatility, but VT's structure mitigates single-country or sector risks. Analyst sentiment is generally positive, emphasizing its role as a core holding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
